scholarly journals Autologous Bone Marrow Cell Infusion for the Treatment of Decompensated Liver Cirrhosis Patients With Type 2 Diabetes Mellitus

2021 ◽  
Vol 12 ◽  
Author(s):  
Baochi Liu ◽  
Mingrong Cheng ◽  
Lin Lang ◽  
Lei Li ◽  
Yanhui Si ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Marrow Cell ◽  
Autologous Bone Marrow ◽  
Control Group ◽  
Observation Group ◽  
Decompensated Liver Cirrhosis ◽  
Autologous Bone ◽  
Time Point

This study aimed to indicate whether autologous bone marrow cell infusion (ABMI) via the right omental vein (ROV) could have a regulatory effect on decompensated liver cirrhosis (DLC) patients with type 2 diabetes mellitus (T2DM). For this purpose, 24 DLC patients with T2DM were divided into observation group (n=14) and control group (n=10). Patients in the observation group were given ABMI through the ROV and right omental artery (ROA), and cases in the control group received ABMI through the ROV. At 1, 3, 6, and 12months after ABMI, it was revealed that the prothrombin time, the total bilirubin levels, and the amount of ascites were significantly lower, while the serum albumin levels in the two groups were markedly higher compared with those before ABMI (p<0.01), and there was no significant difference between the two groups at each time point (p>0.05). The fasting blood glucose and glycosylated hemoglobin levels at 6 and 12months after ABMI in the two groups significantly decreased compared with those before ABMI (p<0.05 or p<0.01), while the decreased levels in the observation group were more obvious than those in the control group at each time point (p<0.01). The amount of insulin in the observation group at 3, 6, and 12months after ABMI was significantly less than that before ABMI in the control group (p<0.01). In summary, ABMI showed a significant therapeutic efficacy for DLC patients with T2DM through ROV and ROA.

Efficacy of Autologous Bone Marrow–Derived Stem Cell Transplantation in Patients With Type 2 Diabetes Mellitus

2009 ◽  
Vol 18 (10) ◽  
pp. 1407-1416 ◽  
Author(s):  
Anil Bhansali ◽  
Vimal Upreti ◽  
N. Khandelwal ◽  
N. Marwaha ◽  
Vivek Gupta ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Bone Marrow ◽  
Type 2 Diabetes Mellitus ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Autologous Bone Marrow ◽  
Autologous Bone

scholarly journals Long term effects of the implantation of autologous bone marrow mononuclear cells for type 2 diabetes mellitus

2012 ◽  
Vol 59 (11) ◽  
pp. 1031-1039 ◽  
Author(s):  
Jianxia Hu ◽  
Chengqian Li ◽  
Li Wang ◽  
Xuefeng Zhang ◽  
Meirong Zhang ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Bone Marrow ◽  
Mononuclear Cells ◽  
Autologous Bone Marrow ◽  
Bone Marrow Mononuclear Cells ◽  
Long Term Effects ◽  
Autologous Bone

Effect of testosterone on lipid metabolism and endothelium in men with type 2 diabetes mellitus and hypogonadism

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
I Khripun ◽  
S Vorobyev ◽  
A Khripun ◽  
M Kogan ◽  
A Demidova ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Lipid Metabolism ◽  
Control Group ◽  
Funding Source ◽  
Carbohydrate And Lipid Metabolism ◽  
Time Point

Abstract Background To date, knowledge about the effects of testosterone (T) on the cardiovascular system of men remains controversial and requires additional research. Especially the putative impact of T replacement therapy (TRT) on lipid metabolism and endothelial dysfunction as a starting mechanism for the development of cardiovascular pathology in men with type 2 diabetes mellitus (T2DM) presenting with T deficiency has to be elucidated. The aim of this work was to evaluate the effect of T replacement therapy on lipid metabolism and function of endothelium in men with T2DM and hypogonadism. Methods The study included 95 men (mean age 55,3±2,4 years) with T2DM and late onset hypogonadism, established according to EAU 2015 criteria. Parameters of carbohydrate and lipid metabolism, as well as ultrasound assessment of flow-mediated dilatation of the brachial artery (FMD-BA) and intima-media thickness (IMT) of brachial arteries were performed at baseline and after 9 months. Patients were randomized into 2 groups: 1 - 45 men receiving TRT, using 1% transdermal T-gel and 2 (control group) - 50 men, who were not assigned to TRT. Statistical analysis was carried out using the Wilcoxon - test for repeated measurements (STATISTICA 10 software package). Results During the treatment period no serious adverse events were registered. The study revealed a significant decrease in HbA1c (p<0.001), total cholesterol (p=0.009), triglycerides (p=0.004) and LDL (p=0.01) levels as well as an increase in HDL level (p=0.001) in the 1st group vs baseline and compared to the 2nd one. There was a decrease in IMT (from 1.0 [0.8; 1.1] to 0.7 [0.6; 0.9] mm, p=0.002) in the 1st group compared to the 2nd (p<0.001). The endothelium-dependent FMD-BA increased 1.5 - fold in men applying T-Gel vs baseline as well as compared to the control group at the time point of follow- up (p<0.001). At the same time TRT leaded to acceleration of the time until maximal vasodilation – it became twice faster (from 120 [90; 120] to 60 [60; 90] sec, p<0.001) compared to baseline and the 2nd group (p<0.001). Linear blood flow velocity increased markedly in the 1st group compared to the 2nd at the time point of follow-up (p=0.03). Conclusion TRT in men with T2DM and T deficiency leads to an improvement in carbohydrate and lipid metabolism together with a significant decrease in IMT and enhancement of endothelium vasomotor function, seems to facilitate a reduction in cardiovascular risk. Funding Acknowledgement Type of funding source: Foundation. Main funding source(s): Russian Science Foundation

scholarly journals CORRECTION: A type 2 diabetes mellitus patient was successfully treated by autologous bone marrow-derived stem cell transplantation: A case report

2019 ◽  
Vol 6 (4) ◽  
pp. 3140
Author(s):  
Phuong Thi-Bich Le ◽  
Nguyen Phu-Van Doan ◽  
Phan Van Tien ◽  
Dang Ngo Chau Hoang ◽  
Ngoc Kim Phan ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Bone Marrow ◽  
Type 2 Diabetes Mellitus ◽  
Blood Glucose ◽  
Fasting Blood Glucose ◽  
Autologous Bone Marrow ◽  
Diabetes Mellitus Patient ◽  
Autologous Bone

In the previous publication with title ”A type 2 diabetes mellitus patient was successfully treated by autologous bone marrow-derived stem cell transplantation: A case report”1, page 2968, in the Table 1, the unit for fasting blood glucose and blood glucose 2 hours after meals is mg/dL; however, the corrected unit for fasting blood glucose and blood glucose 2 hours after meal is mmol/L.  

scholarly journals Loss of microRNA Expression is Involved in the Development and Prognosis of Breast Cancer Complicated by Type 2 Diabetes Mellitus

2016 ◽  
Vol 31 (4) ◽  
pp. 368-374 ◽  
Author(s):  
Huan-tao Liu ◽  
Yin-Tao Xu ◽  
Hui-Ying Li ◽  
Jia Zhao ◽  
Hui-Yuan Zhai ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Control Group ◽  
Observation Group ◽  
Node Metastasis ◽  
History Of ◽  
Er Status

Objective To explore the relationships of the expression of miR-145 to the clinicopathological characteristics and prognosis of patients with breast cancer complicated by type 2 diabetes mellitus (T2DM). Methods A total of 257 female patients with breast cancer were enrolled for our experiment, including 140 patients with simple breast cancer (control group) and 117 patients with breast cancer complicated by T2DM (observation group). Patients were treated with modified radical mastectomy supplemented with radiotherapy, chemotherapy and endocrine therapy. qRT-PCR was used for the detection of miR-145 expression in patients of both groups. Follow-up lasted 13-60 months. Results The relative expression of miR-145 in the observation group was significantly lower than that in the control group (p<0.05). The expression of miR-145 in patients with breast cancer complicated by T2DM was related to the history of diabetes, tumor node metastasis (TNM) stage, tumor size, lymph node metastasis (LNM), estrogen receptor (ER) status, and HER2 (all p<0.05). The median disease-free survival (DFS) was significantly longer and the 5-year DFS rate significantly higher in the high-expression group than in the low-expression group. History of diabetes, TNM stage, tumor size, LNM, ER status, and HER2 were risk factors for patients with breast cancer complicated by T2DM (all p<0.05). Conclusions Loss of miR-145 expression is related to the development of breast cancer complicated by T2DM, and low miR-145 expression might be an adverse prognostic factor in patients with this disease.

scholarly journals A type 2 diabetes mellitus patient was successfully treated by autologous bone marrow-derived stem cell transplantation: A case report

2019 ◽  
Vol 6 (1) ◽  
pp. 2966-2969 ◽  
Author(s):  
Phuong Thi-Bich Le ◽  
Nguyen Phu-Van Doan ◽  
Phan Van Tien ◽  
Dang Ngo Chau Hoang ◽  
Ngoc Kim Phan ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Bone Marrow ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Autologous Bone Marrow ◽  
Insulin Injection ◽  
Autologous Bone

Introduction: Type 2 diabetes mellitus (T2DM) iscurrently one of the most common diseases as a result of obesity and aging. Currently, T2DMis treated by various methods, such as insulin injection and glucose regulation agents. In this report, we report the case of a T2DM patient who was successfully treated by autologous bone marrow-derived stem cell transplantation. Methods: The patient was diagnosed with T2DM by standard methods for more than ten years. The patient agreed to be treated by the new approach – autologous bone marrow-derived stem cell transplantation. The bone marrow was collected from the patient twice at 100 mL volume each time. The stem cellenriched mononuclear cells (MNCs) in the bone marrow were isolated by gradient centrifugation. MNCs were intravenously transfused into the patient twice within the 1-month interval. The lasting glucose and 2h-after meal glucose, as well as hemoglobin A1c (Hab1c), were recorded before transplantation, and 1-, 3-, and 6-months post-transplantation. Results: The results showed that there were no adverse effect recorded during the monitoring period, and that the T2DM symptoms significantly improved. After the first round of transplantation, the glucose level reduced considerably and continued to decrease out to 3 months. Meanwhile, after 2 months of transplantation, the Hab1C level decreased and achieved the average level at the 3rd month of treatment. After 6 months, the patient was free from insulin injection and maintained glucose and Hab1c level. To date, after 9 months of treatment; the patients has continued to be free from insulin injection and without any adverse effects. Conclusion: The primary results have suggested that autologous bone marrow-derived stem cell transplantation may be a new direction for T2DM treatment.  

scholarly journals Effect of Paroxetine Combined with Probiotics in Patients with Type 2 Diabetes Mellitus Complicated with Gastrointestinal Dysfunction and Liver Cancer

2021 ◽  
Vol 2021 ◽  
pp. 1-5
Author(s):  
Yi Peng ◽  
Xingxia Yang ◽  
Yeju Wang
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Liver Cancer ◽  
Nutritional Status ◽  
Control Group ◽  
Hamilton Depression Scale ◽  
Observation Group ◽  
Gastrointestinal Dysfunction

Background. To explore the effect of paroxetine combined with probiotics in patients with type 2 diabetes mellitus with gastrointestinal dysfunction and liver cancer and its effect on nutritional status. Materials and Methods. 96 patients with type 2 diabetes mellitus combined with gastrointestinal dysfunction and liver cancer were selected as subjects from March 2018 to March 2021. They were randomly divided into control group and observation group, with 48 cases in each group. The control group was treated with probiotics, and the observation group was combined with paroxetine on the basis of the control group. After 4 weeks of treatment, the gastrointestinal mucosal function, nutritional status, Hamilton Depression Scale (HAMD) and Hamilton Anxiety Scale (HAMA) score, and the safety were compared between the two groups. Results. The levels of D-lactic acid, PCT, and endotoxin in the observation group were (1.75 ± 0.38), (4.39 ± 0.79), and (0.20 ± 0.06), respectively, which were significantly lower than those in the control group (2.69 ± 0.46), (7.84 ± 1.32), and (0.29 ± 0.08) ( P < 0.05 ). Moreover, the nutritional status TP, ALB, Hb, PA, and TLC levels of the observation group were higher than those of the control group ( P < 0.05 ). The HAMA and HAMD scores in the observation group were (5.76 ± 1.06) and (8.94 ± 1.26), respectively, which were significantly lower than those in the control group (10.69 ± 2.21) and (13.42 ± 2.34) ( P < 0.05 ). However, there was no statistical significance in the incidence of nausea and vomiting, blurred vision, chest arthralgia, palpitation, anaesthesia, dizziness, and drowsiness between the two groups ( P > 0.05 ). Conclusions. Paroxetine combined with probiotics could help to improve the gastrointestinal mucosal function of patients with type 2 diabetes mellitus complicated with gastrointestinal dysfunction and liver cancer, improve the nutritional status of patients, and reduce anxiety and depression, and the drug was safe and worthy of promotion and application.

Sign in / Sign up

Export Citation Format

Share Document